Literature DB >> 17010118

Adiponectin and insulin resistance in early- and late-onset pre-eclampsia.

R D'Anna1, G Baviera, F Corrado, D Giordano, A De Vivo, G Nicocia, A Di Benedetto.   

Abstract

OBJECTIVE: To evaluate the importance of adiponectin and insulin resistance in early- and late-onset pre-eclampsia.
DESIGN: A nested case-control study in 72 pregnant women who participated in the first-trimester Down-syndrome-screening programme and who delivered at our hospital.
SETTING: University Hospital, Department of Obstetrics and Gynecology. POPULATION: Pregnant women: 36 women with pre-eclampsia of which 20 late onset and 16 early onset were compared with 36 uncomplicated pregnancies who delivered at term.
METHODS: In all the women, insulin resistance was calculated by the homeostasis model assessment ratio (HOMA-IR) and plasma adiponectin was determined using an enzyme-linked immunosorbent assay. MAIN OUTCOME MEASURES: Insulin resistance and adiponectin concentration.
RESULTS: First-trimester plasma adiponectin mean levels in the whole pre-eclampsia group were significantly lower than that in the control group (8.4 +/- 3.3 versus 14.8 +/- 4.6 microgram/ml; P < 0.001), whereas first-trimester mean HOMA-IR values were significantly higher in the pre-eclampsia group than that in the control group (2.0 +/- 1.1 versus 1.0 +/- 0.4; P= 0.01). Plasma adiponectin concentrations at delivery in the pre-eclampsia group were significantly higher than that in the control group (9.2 +/- 3.7 versus 7.8 +/- 2.6 microgram/ml; P= 0.04). First-trimester plasma adiponectin mean concentrations in the late-onset subgroup were significantly lower compared with the concentrations in early-onset subgroup (6.2 +/- 1.4 microgram/ml versus 11.1 +/- 3.2 microgram/ml; P < 0.001), and there was a significant difference in adiponectin plasma values only between women in the late-onset pre-eclampsia group versus those in the control group (P < 0.001). First-trimester mean HOMA-IR values were significantly higher in the late-onset subgroup compared with that of the early-onset subgroup (2.5 +/- 1.3 versus 1.3 +/- 0.3; P= 0.02), and there was a significant difference only between the control group versus the late-onset subgroup (P= 0.001).
CONCLUSIONS: First-trimester adiponectin and HOMA-IR values seem to select two completely different populations: early- and late-onset pre-eclampsia, which might suggest a different pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17010118     DOI: 10.1111/j.1471-0528.2006.01078.x

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  31 in total

Review 1.  The role of adiponectin in reproduction: from polycystic ovary syndrome to assisted reproduction.

Authors:  Konstantinos G Michalakis; James H Segars
Journal:  Fertil Steril       Date:  2010-06-19       Impact factor: 7.329

2.  Intraabdominal fat, insulin sensitivity, and cardiovascular risk factors in postpartum women with a history of preeclampsia.

Authors:  Darcy R Barry; Kristina M Utzschneider; Jenny Tong; Kersten Gaba; Daniel F Leotta; John D Brunzell; Thomas R Easterling
Journal:  Am J Obstet Gynecol       Date:  2015-05-21       Impact factor: 8.661

3.  The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention.

Authors:  Liona C Poon; Andrew Shennan; Jonathan A Hyett; Anil Kapur; Eran Hadar; Hema Divakar; Fionnuala McAuliffe; Fabricio da Silva Costa; Peter von Dadelszen; Harold David McIntyre; Anne B Kihara; Gian Carlo Di Renzo; Roberto Romero; Mary D'Alton; Vincenzo Berghella; Kypros H Nicolaides; Moshe Hod
Journal:  Int J Gynaecol Obstet       Date:  2019-05       Impact factor: 3.561

Review 4.  Why are kids with lupus at an increased risk of cardiovascular disease?

Authors:  Catherine Quinlan; Stephen D Marks; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2015-09-23       Impact factor: 3.714

Review 5.  Adiponectin receptor signalling in the brain.

Authors:  John Thundyil; Dale Pavlovski; Christopher G Sobey; Thiruma V Arumugam
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

6.  Retinol binding protein 4--a novel association with early-onset preeclampsia.

Authors:  Edi Vaisbuch; Roberto Romero; Shali Mazaki-Tovi; Offer Erez; Sun Kwon Kim; Tinnakorn Chaiworapongsa; Francesca Gotsch; Nandor Gabor Than; Zhong Dong; Percy Pacora; Ronald Lamont; Lami Yeo; Sonia S Hassan; Juan Pedro Kusanovic
Journal:  J Perinat Med       Date:  2010-03       Impact factor: 1.901

7.  Maternal serum adiponectin multimers in gestational diabetes.

Authors:  Shali Mazaki-Tovi; Roberto Romero; Edi Vaisbuch; Offer Erez; Pooja Mittal; Tinnakorn Chaiworapongsa; Sun Kwon Kim; Percy Pacora; Lami Yeo; Francesca Gotsch; Zhong Dong; Bo Hyun Yoon; Sonia S Hassan; Juan Pedro Kusanovic
Journal:  J Perinat Med       Date:  2009       Impact factor: 1.901

8.  Maternal serum adiponectin multimers in patients with a small-for-gestational-age newborn.

Authors:  Shali Mazaki-Tovi; Roberto Romero; Edi Vaisbuch; Offer Erez; Pooja Mittal; Tinnakorn Chaiworapongsa; Sun Kwon Kim; Percy Pacora; Lami Yeo; Francesca Gotsch; Zhong Dong; Bo Hyun Yoon; Sonia S Hassan; Juan Pedro Kusanovic
Journal:  J Perinat Med       Date:  2009       Impact factor: 1.901

9.  Characterization of visceral and subcutaneous adipose tissue transcriptome in pregnant women with and without spontaneous labor at term: implication of alternative splicing in the metabolic adaptations of adipose tissue to parturition.

Authors:  Shali Mazaki-Tovi; Adi L Tarca; Edi Vaisbuch; Juan Pedro Kusanovic; Nandor Gabor Than; Tinnakorn Chaiworapongsa; Zhong Dong; Sonia S Hassan; Roberto Romero
Journal:  J Perinat Med       Date:  2016-10-01       Impact factor: 1.901

10.  Adiponectin in severe preeclampsia.

Authors:  Jyh Kae Nien; Shali Mazaki-Tovi; Roberto Romero; Offer Erez; Juan Pedro Kusanovic; Francesca Gotsch; Beth L Pineles; Ricardo Gomez; Samuel Edwin; Moshe Mazor; Jimmy Espinoza; Bo Hyun Yoon; Sonia S Hassan
Journal:  J Perinat Med       Date:  2007       Impact factor: 1.901

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.